Investigating the impact of renal therapy on carbon dioxide removal efficiency
The Effect of Continuous Renal Replacement Therapy on the Efficiency of Extracorporeal CO2 Removal
This study tests how two types of kidney treatments can help remove carbon dioxide more effectively in patients with breathing problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Southeast University, China Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT05989971 on ClinicalTrials.gov |
What this trial studies
This study examines how continuous renal replacement therapy (CRRT) affects the efficiency of extracorporeal carbon dioxide removal (ECCO2R) in patients with respiratory failure and hypercapnia. It focuses on two methods of CRRT: continuous veno-venous hemofiltration (CVVH) and continuous veno-venous hemodialysis (CVVHD). The research aims to understand how the bicarbonate concentration changes during these processes influence CO2 clearance efficiency in an in vitro setting. By analyzing these interactions, the study seeks to optimize treatment strategies for patients requiring ECCO2R.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 85 who are undergoing extracorporeal carbon dioxide removal combined with continuous renal replacement therapy.
Not a fit: Patients with severe hemodynamic instability or significant electrolyte deficiencies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the effectiveness of CO2 removal in patients with respiratory failure, potentially improving their clinical outcomes.
How similar studies have performed: While this approach is innovative, similar studies have not been widely reported, indicating that this may be a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Using Extracorporeal carbon dioxide removal combined with continuous renal replacement therapy * 18 years ≤ age ≤ 85 years; Exclusion Criteria: * Severe hemodynamic instability (increased dosage of vasoactive drugs or MAP ≤ 65mmHg within two hours); * Severe electrolyte deficiency (including severe hyponatremia (blood sodium\<130mmol/L) and hypokalemia (blood potassium\<3.0mmol/L)); * Participate in other intervention studies within 30 days; * Do not consent this research
Where this trial is running
Nanjing, Jiangsu
- Ling Liu — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Ling Liu
- Email: liulingdoctor@126.com
- Phone: +86 13851435472
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.